# DESCRIPTION

## BACKGROUND

- describe HIV virion assembly

## BRIEF SUMMARY

- introduce lentiviral vector

## DETAILED DESCRIPTION

- introduce patent application structure and terminology

### A. Definitions

- define terminology used in patent application
- explain singular and plural forms of words
- describe optional and optional ranges

### B. Nucleic Acid Sequences

- introduce nucleic acid sequences with modified HIV Gag sequence
- describe exogenous sequence of interest
- explain therapeutic and detection agents
- detail flanking sequences and cleavage sites
- describe additional HIV genes and mutated Env gene
- summarize modified HIV Gag sequence variants and derivatives

### C. Vectors

- define vectors
- describe viral based delivery systems
- describe non-viral based delivery systems
- discuss control elements in expression vectors
- describe polyadenylation regions

### D. Recombinant Lentivirus

- describe recombinant lentiviruses or virions
- discuss chimeric Gag proteins and HIV particles

### E. Recombinant Cells

- describe recombinant cells comprising nucleic acid sequences, vectors or lentiviruses

### F. Methods of Producing Recombinant Lentiviruses

- describe methods of producing recombinant lentiviruses using vectors and envelope plasmids
- discuss two and three plasmid systems for producing recombinant lentiviruses

### G. Methods of Treating

- describe methods of treating a subject with a therapeutic agent using recombinant lentiviruses

### H. Methods of Monitoring

- describe methods of monitoring lentivirus morphogenesis using detection agents

### I. Kits

- describe kits for producing recombinant lentiviruses

## Examples

### A. Materials and Methods

- describe experimental setup
- outline protocols for various assays

### B. Results

- present data on virion release and maturation
- show infectivity of R8.2:Gag-Fluo vectors

### C. Discussion

- interpret results and discuss implications

